Abstract:Targeting Glutathione peroxidase 4 (GPX4) has become a promising strategy for drug-resistant cancer therapy via ferroptosis induction. It was found that the GPX4 inhibitors such as RSL3 have GPX4 degradation ability via not only autophagy-lysosome pathway but also ubiquitin-proteasome system (UPS). Proteolysis targeting chimeras (PROTACs) using small molecule with both inhibition and degradation ability as the ligand of protein of interest (POI) have not been reported. To obtain better compounds with effective disturbance of GPX4 activity, and compare the difference between GPX4 inhibitors with degradation ability and their related PROTACs, we designed and synthesized a series of GPX4 degraders using PROTAC technology in terms of its excellent characteristics such as high efficiency and selectivity and the capacity of overcoming resistance. Hence, 8e was discovered as a potent and highly efficacious GPX4 degrader based upon the inhibitor RSL3. It was 2–3 times more potent than RSL3 in all the in vitro anti-tumor assays, indicating the importance of the PROTAC ternary complex of GPX4, 8e and E3 ligase ligand. 8e revealed better potency in resistant tumor cells than in wide type cells. Furthermore, we discovered for the first time that degrader 8e exhibit GPX4 degradation activity via ubiquitin-proteasome system (UPS) and autophagy-lysosome pathway with UPS plays the major role in the process. Our data also suggested that 8e and RSL3 could potently induce ferroptosis of HT1080 cells via GPX4 inhibition and degradation. In summary, our data revealed that the GPX4 degrader 8e achieves better degradation and anti-tumor effects compared to its related GPX4 inhibitor RSL3. Thus, an efficient strategy to induce GPX4 degradation and subsequent ferroptosis was established in this study for malignant cancer treatment in the future.

Structure-activity relationship study of RSL3-based GPX4 degraders and its potential noncovalent optimization

Discovery of a Potent Chloroacetamide GPX4 Inhibitor with Bioavailability to Enable Target Engagement in Mice, a Potential Tool Compound for Inducing Ferroptosis in Vivo.

Dual degradation mechanism of GPX4 degrader in induction of ferroptosis exerting anti-resistant tumor effect

Design, synthesis, and biological evaluation of RSL3-based GPX4 degraders with hydrophobic tags

Design and Synthesis of Proteolysis-Targeting Chimeras (protacs) As Degraders of Glutathione Peroxidase 4.

A potent GPX4 degrader to induce ferroptosis in HT1080 cells

ZX703: A Small-Molecule Degrader of GPX4 Inducing Ferroptosis in Human Cancer Cells

Intracellular Delivery of Glutathione Peroxidase Degrader Induces Ferroptosis in Vivo

Targeting GPX4 in ferroptosis and cancer: chemical strategies and challenges

Novel Allosteric Activators for Ferroptosis Regulator Glutathione Peroxidase 4.

GPX4 allosteric activators inhibit ferroptosis and exert myocardial protection in doxorubicin-induced myocardial injury mouse model

Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles

Discovery of ML210-Based glutathione peroxidase 4 (GPX4) degrader inducing ferroptosis of human cancer cells

PDTAC: Targeted Photodegradation of GPX4 Triggers Ferroptosis and Potent Antitumor Immunity

A GPX4 non-enzymatic domain and MDM2 targeting peptide PROTAC for acute lymphoid leukemia therapy through ferroptosis induction

Discovery of GPX4 inhibitors through FP-based high-throughput screening

Small-molecule allosteric inhibitors of GPX4

Discovery of a Potent Glutathione Peroxidase 4 Inhibitor As a Selective Ferroptosis Inducer.

Recent Progress of Glutathione Peroxidase 4 Inhibitors in Cancer Therapy

A Potent and Selective Anti-Glutathione Peroxidase 4 Nanobody as Ferroptosis Inducer

Discovery of Novel Potent Covalent Glutathione Peroxidase 4 Inhibitors as Highly Selective Ferroptosis Inducers for the Treatment of Triple-Negative Breast Cancer